Tuesday, January 5, 2021
Monday, January 4, 2021
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up
Delta, Kelowna, BC, January 4, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/010421-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/01041Round-Up-2020.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be taking a quick look back at 2020 and the year’s main highlights.
Sales Growth:
While COVID-19 has had a significantly negative impact on most industries this year, the cannabis sector has seen substantial sales growth month over month as the year has progressed. This can be attributed to many factors related to COVID measures as well as to the success and growth of the industry itself.
One of the first contributing factors that helped sales growth this year was the very different place the entire industry was at the start of 2020 when compared to years previous. Supply issues were a massive factor contributing to lower sales in 2018 and 2019 in Canada and in the US, multi-state operators were still in the process and gaining the footing and building out their infrastructure. Looking at the start of 2020 we saw in Canada that many of the large scale producers who struggled in the first two years finally hit their stride as far as product supply levels and quality and consistency of their products. We also began to see the development of a premium bud segment in the industry through partnerships with smaller niche cultivators and the Cannabis 2.0 products that had been in the wing for months finally started hitting retail shelves. The retail development within Canada was also in a much more stable and built out position starting in 2020 than in other years with private retail stores in BC and Ontario, the two most populous provinces, seeing massive growth.
Image courtesy of: MJBIZ Daily
With the industry being in a much better starting position entering 2020, the next big factor to impact sales was obviously COVID-19 and lockdowns.
In Canada with so many people stuck at home due to lockdown procedures and mahy receiving government aid checks from being out of the work, we saw a massive spike in Cannabis usage and sales as many who were on the fence socially about this substance in years previous changed their perception.
This was also massively aided by Cannabis businesses being deemed essential in both the US and Canada as well as other parts of the world where legal cannabis operations are in place. This change from Illegal to essential brought many new consumers to the market and has helped remove some of the long standing stigma surrounding the industry.
These contributing factors which aided to sales gave many companies in the industry the much needed revenue boost they had been waiting for and allowed many companies the time and financial resources to begin expansion and innovation.
Industry Innovation:
Increased sales and revenues in many ways helped stabilize what was previously a very unstable industry, which allowed many to use the time to innovate and expand.
We saw a plethora of Cannabis 2.0 products that had been stuck in development hell for months finally begin hitting shelves and as more products hit retail stores we saw competitors continue to innovate and adapt their products to consumers needs as the year progressed.
Not only did many companies innovate with regards to their products but we also saw many retailers build out their online capabilities and begin offering delivery and cubside services, where regulators allowed, which again helped increase their customer share and overall sales.
Now most of the US and Canadian cannabis retail sector offers online sales, delivery or curbside pickup as well as touchless transactions and interactive menus, all features that had been slowly developing over the last two years but suddenly saw a massive jump in 2020 due to the necessity for innovation COVID created.
This also translated to the underserved medical community who saw massive growth in Telemedicine usage globally and in medical cannabis countries, there were serious adjustments to the overall medical industry which now allows for easier access to cannabis medication, delivery and curbside pick up options, telemedicine prescription and information access as well as a massive growth in product selection and inventory.
Continued Legalization and Social Acceptance:
While I had already mentioned the massive social change created from Cannabis businesses being deemed essential this year, there was also another huge shift in the US, as well as globally towards cannabis reform policy and general drug reform policy.
This year saw many new states in the US vote for cannabis reform such as New Jersey, Montanna, Arizona and South Dakota, which all voted in favor of cannabis reform. We also saw states like Oregan set new drug policy precedent in the US by voting in favor of decriminalizing virtually all drugs and legalizing medicinal psilocybin.
On a global scale we saw more countries in South America extend or improve their cannabis drug policies in favour of import and export opportunities and increased medical availability. One of the largest holdouts as well as probably one of the largest potential markets, Mexico looks to have some sort of medical cannabis program in place in 2021, though regulatory progress has been slow so far. Even in South East Asia we have seen a growing leniency towards CBD products with some countries beginning the process of implementing a medical cannabis program, again most likely in 2021 or 2022.
In the EU, while we haven’t seen any major changes to the legal landscape, 2020 did help continue to build out the EU infrastructure for the medical and CBD industry and we have seen massive growth when it comes to import and export markets.
What’s Next?
Looking ahead at 2021 and beyond there's a lot of hype and expectation surrounding the cannabis industry once again. One of the best things to come out of 2020 has been increased investor confidence and interest in this industry that saw a large investment slump since legalization in Canada in 2018. Many of the the industries largest companies are now trading back up at their regular prices and many smaller companies have had their best trading year to date.
This increase in investor and consumer confidence in the industry should help push some of the last needed advancements in regulation and industry reform to boost the cannabis industry into the same social and societal acceptance of alcohol, if not allowing it surpass alcohol due to alcohol's many negative health impacts.
Looking at the US in 2021 we can definitely expect more speculation and hype surrounding the idea of either Safe Banking Access or decriminalization of cannabis, at least one of these outcomes seems likely this year. We have seen many companies in both the US and Canada preparing for the merging of markets and with the implementation of at least Safe Banking Access a floodgate of investor capital becomes available to US based cannabis companies.
Looking at Canada, there is expectation of regulatory reform surrounding delivery access in some provinces, private retail expansion as well a hopeful reevaluation of dosage and packaging restrictions, all of which would greatly benefit overall industry.
Looking globally and at the industry as a whole, South American expansion of both medical and recreational markets seems inevitable as does expansion of the EU recreational market. There is a lot of excitement surrounding South East Asian markets establishing medical markets though this looks to be further out than 2021, though CBD products are very much in play. Finally we have seen a lot of infrastructure build out in Israel and parts of Africa, both of which could have massive impacts on the global pricing of Cannabis and CBD products as well as the import and export markets.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Thursday, December 31, 2020
Wednesday, December 30, 2020
Investor Ideas #Potcasts 511, #Cannabis News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C) (CSE: $NOVA.C)
Investor Ideas #Potcasts 511, #Cannabis News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C) (CSE: $NOVA.C)
Delta, Kelowna, BC, December 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/123020-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12301ALID-PULL-NOVA.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few private and public company announcements, specifically focussing on the psychedelic sector.
SYNTAC Institute, an Alberta-based non-profit organization dedicated to bringing legal psychedelic-assisted therapy to Canadians, recently confirmed that it has facilitated the first announced approval from Health Canada for an Alberta-based patient facing a terminal illness diagnosis.
The legal exemption from the Canadian Drugs and Substances Act, granted by the Office of Controlled Substances at Health Canada, paves the way for Calgary resident Anthony White to immediately undergo psilocybin-assisted treatment to deal with the severe mental health challenges that come with a terminal medical diagnosis. White's situation has been even more difficult to contend with as he is in his forties and has a young daughter.
Under the Section 56 Exemption approved by Health Canada, White will now be eligible to participate in a therapy process overseen by a medical team that includes the use of psilocybin, an active hallucinogenic substance found in "magic mushrooms".
"Facing this devastating prognosis has been incredibly difficult, but I am grateful I can soon gain some comfort and relief through this promising therapy. I appreciate the help from the folks at SYNTAC to bring this to reality, and to Health Canada for putting the patient first in this important decision."
Encouraging research continues to emerge that suggests psychedelic-assisted therapeutic approaches to mental and emotional health conditions demonstrate remarkable efficacy and outcomes for a variety of conditions including end-of-life distress, Post Traumatic Stress Disorder (PTSD), depression and anxiety.
"We are extremely grateful to Health Canada and the Hon. Minister Hajdu and her team for delivering this exemption so that Mr. White can immediately access this innovative therapy," stated David Harder, Executive Director of SYNTAC Institute in Calgary.
"We are also deeply appreciative of the tireless efforts of Dr. Bruce Tobin and his team at Therapsil in Victoria B.C. for putting in so much of the groundwork required for this kind of announcement to be possible."
With the traditional approach to mental health and wellness in Canada already struggling, COVID-19 is creating a tsunami of mental and emotional health challenges that threaten to overwhelm the Canadian healthcare system. "We believe psychedelic medicines will be a huge part of the solution that Canadians need and deserve", added Harder.
"We are not only incredibly thrilled for Mr. White gaining immediate access to this powerful therapeutic tool, but also for every Canadian who is suffering with mental and emotional health challenges. This is another step forward in the battle against our country's mental health crisis."
Allied Corp (OTCQB: ALID) – an international medical cannabis company focused on creating and providing health solutions to address today’s medical mental health issues, recently announced the signing of a letter of intent to acquire the psilocybin company Pacific Sun Fungi. This further expands upon Allied’s press release of October 20, 2020 communicating the submission of the provisional patent for Allied’s functional mushroom formulation targeting major depression and anxiety.
Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years. Pacific Sun holds several formulations that have been tested under physician supervision. Pacific Sun also has proprietary extraction technology, proprietary formulations for several specific disease targets and physician-led therapy protocols that have proven to be effective for several specific disease targets.
Over the past two years, in parallel with psilocybin moving into the pharmaceutical research realm, Allied has continued to develop its pharmaceutical research infrastructure. This represents the evolution of Allied beyond specific cannabis-based therapies to more pharma-based health targets.
Allied was born out of the need to support veterans and first responders suffering from PTSD with targeted cannabinoid solutions. This acquisition has advanced Allied into the broader mental health market encompassing both pharmaceutical and natural health products. Building upon our experience with PTSD, we are expanding our research and treatment options to encompass depression, anxiety and general mental health. This puts Allied in the unique position to provide a full-scope, closed-loop therapy protocol. Typical psilocybin therapies support the patient for an episodic micro-dosing treatment regime which follows a specific dosing and wash out cycle. Unfortunately, this leaves the patient with a treatment gap between dosing periods. This can now be bridged with Allied’s existing cannabinoid treatment solutions. A “full scope treatment” option.
The proprietary “Allied full scope treatment” offers the patient continual therapy with treatment options both before and after the psilocybin treatment period. This is accomplished by offering Allied’s cannabinoid and natural health products combined with the psilocybin products and protocols. This will all be accomplished under legal license and physician supervision.
A timeline leading towards Allied as being positioned as a leader in this space:
● In 2018, the FDA recognized psilocybin therapies as a “breakthrough” therapy for PTSD and Major Depressive Disorder. (Food and Drug Administration, 2018).
● In 2019, Imperial College of London and John Hopkins open the first psychedelic research centers. MAPS clinics across the nation conduct research on psilocybin therapy. (Forbes.com, 2019).
● In 2020, Health Canada approves psilocybin for select patient with terminal illness. 2020 Oregon State decriminalizes psilocybin. On November 30, 2020 Oregon state issues call for participants in State Guidance Committee. Allied executive applies to be a member of this committee. (Health Canada, 2020 and Oregon State Health, 2020).
● On October 20, 2020, Allied submits provisional patent on drug formulation containing psilocybin and a combination of additional functional mushrooms for the disease targets of PTSD, depression and general anxiety. (Allied Corp press release of Oct 20, 2020).
● On December 20th, 2020, Allied moves to acquire Pacific Sun Fungi by signing Letter of Intent to acquire.
Allied’s initial focus will be on pharmaceutical R&D while also entering the Oregon State market with additional markets to follow as legislation allows. As well, Allied is in the process of applying for a Section 56 exemption in Canada for Allied’s Physician group to be able to prescribe Allied’s formulation to veterans and first responders. With this infrastructure in place, Allied will be able to be one of the first companies to come to market in the psilocybin space with both psilocybin products augmented by Allied’s current natural health and cannabis-derived pharma products.
Pure Extracts Technologies Corp. (CSE: PULL) announced that it is commencing a study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to the Company.
The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms that could be used in future efficacy clinical trials by both Pure Extracts and its pharmaceutical customers. Clinical batch manufacturing, packaging and labelling are all included in the study as is conformity testing and stability testing (including both long-term and accelerated). The study will conform to both Canadian Good Manufacturing Practice (“GMP”) and Good Clinical Practice (“GCP”) standards.
Dr. MacGregor is a pharmaceutical science inventor, an expert in pharmaceutical technology and novel drug delivery systems. He is a recipient of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies most notably from Canada, US, Australia, Europe, Latin America, China, India and Japan. Dr. MacGregor’s inventions have led to groundbreaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections and post-operative pain. His company has a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA) and is thus licensed to possess psychedelic drug compounds.
Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of TIPT, one of Canada’s premiere pharmaceutical R&D companies, while waiting to receive our Dealer’s License from Health Canada is invaluable. We are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics and to be furthering our knowledge-base in psilocybin and associated novel delivery mechanisms.”
Nova Mentis Life Science Corp. (CSE: NOVA) (OTC: LIBFF)
announced that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeruginascin. NOVA is currently developing C-GMP API psilocybin at its U.S. partner's facility which has highly trained quality control staff on site and certifies all release testing prior to human studies. Per contractual agreements, NOVA has ownership of the API Drug Master Files ("DMF's"), which will be used for regulatory submission prior to commencing human clinical trials.
"The availability of greater than 95 per cent pure synthetic psilocybin, baeocystin and aeruginascin will allow the creation of unique combinatory formulations with potential therapeutic applications to various subsets of ASD," stated Marvin S. Hausman MD, Chairman of NOVA's Scientific Advisory Board. "Furthermore, the availability of these compounds will allow our collaborative scientific chemists to develop technology to deliver our proprietary formulations to organ systems outside of the brain. Are there tryptamine related therapeutic receptors in the small intestine, colon and liver that need to be discovered?"
Baeocystin is an analog of psilocybin and is found in most psilocybin mushrooms along with other minor tryptamine derivatives. Aeruginascin is also a tryptamine derivative and an analog of psilocybin, but it occurs naturally within a different mushroom, Inocybe aeruginascens. The pharmacological effects of both of these compounds are not well understood and anecdotal usage reports reveal different euphoric experiences.
It is theorized that psilocybin and mushroom tryptamine derivatives, such as baeocystin and aeruginascin, when utilized in concert, may produce what is referred to as an "entourage effect". This theory was proposed for cannabis compounds but essentially is applicable to other compounds within natural foods that work together to create unique effects and benefits.
Pending final production of the additional API compounds, NOVA plans to test their efficacy and potential "entourage effect" related therapeutic benefits in the autism spectrum disorder (ASD) preclinical rat model that was designed by Dr. Viviana Trezza at Roma Tre University, Rome, Italy.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Subscribe to:
Posts (Atom)